论文部分内容阅读
目的评价改良CHOPE方案治疗CHOP方案失败的弥漫大B细胞淋巴瘤(DLBCL)的疗效及患者不良反应。方法 2006-09-2009-09对CHOP方案治疗失败的9例DLBCL患者,应用CHOPE方案治疗,采用替尼泊苷(VM-26)每天50 mg/m2,多柔比星(ADM)每天10 mg/m2,长春新碱(VCR)每天0.4 mg/m2,持续静脉滴注第1~4天,环磷酰胺(CTX)每天750 mg/m2静脉注射第6天,泼尼松每天60 mg/m2口服第1~5天,21 d为一个疗程,至少应用2个疗程。结果评价疗效者9例,总有效率55.5%,其中完全缓解2例(22.2%),部分缓解3例(33.3%),评价不良反应的疗程32个,主要不良反应为骨髓抑制(66%),其中发生Ⅳ度骨髓抑制9%。结论改良CHOPE方案可作为CHOP方案治疗失败的DLBCL的有效且基本可耐受的挽救方案。
Objective To evaluate the efficacy and adverse reactions of modified CHOPE regimen in the treatment of diffuse large B cell lymphoma (DLBCL) with failed CHOP regimen. Methods From September 2006 to September 2009, nine patients with DLBCL who failed the treatment with CHOP regimen were treated with CHOPE regimen. The daily dose of VM-26 was 50 mg / m2, while that of doxorubicin (ADM) 10 mg / / m2, vincristine (VCR) daily 0.4 mg / m2, continuous intravenous infusion of 1 to 4 days, cyclophosphamide (CTX) daily 750 mg / m2 intravenous injection on the 6th day, prednisone 60 mg / m2 Oral 1 to 5 days, 21 d for a course of treatment, at least two courses of treatment. Results Nine patients were evaluated and the total effective rate was 55.5%. Complete remission was achieved in 22 cases (22.2%), partial remission in 3 cases (33.3%), adverse reactions were evaluated in 32 cases, and the main adverse reactions were myelosuppression (66%). , Of which IV degree myelosuppression occurred 9%. Conclusion The modified CHOPE regimen is an effective and basically tolerable salvage strategy for DLBCL with failed CHOP regimen.